(NYSE: JNJ) Johnson & Johnson's forecast annual revenue growth rate of 3.28% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.59%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.92%.
Johnson & Johnson's revenue in 2024 is $85,159,000,000.On average, 6 Wall Street analysts forecast JNJ's revenue for 2024 to be $212,616,451,445,461, with the lowest JNJ revenue forecast at $212,176,718,944,153, and the highest JNJ revenue forecast at $213,197,578,583,052. On average, 6 Wall Street analysts forecast JNJ's revenue for 2025 to be $218,215,115,390,760, with the lowest JNJ revenue forecast at $216,428,867,556,397, and the highest JNJ revenue forecast at $220,679,209,593,220.
In 2026, JNJ is forecast to generate $226,474,599,966,797 in revenue, with the lowest revenue forecast at $222,629,203,014,975 and the highest revenue forecast at $232,200,343,244,744.